Compound Radar

Mirum Pharmaceuticals, Inc. (MIRM) Stock Analysis

United States · Healthcare / Biotechnology

Price $99.53
Market cap $6.07B
Next earnings Nov 4, 2026
Entry status Watch $89.11–$94.63

Last updated Sep 8, 2026

Health Check

Last analyzed Sep 7, 2026

45
45/100 Speculative
  • Financial Health 30
  • Profitability 70
  • Business Quality 75
  • Balance Sheet 30
  • Cash Flow 70

Why this rating?

Health 45/100 — Speculative

Strongest Business Quality 75/100
Softest Balance Sheet 30/100
Watch

Worth tracking, but timing is mixed — not a clear setup yet.

Company overview

Mirum Pharmaceuticals, Inc. (MIRM) is a Biotechnology company in the Healthcare sector. Compound Radar rates Mirum Pharmaceuticals, Inc. 45/100 (Speculative) due to high business quality, strong revenue growth, and elevated leverage.

Investment profile

  • Quality High
  • Growth Strong
  • Balance Sheet Stretched

Financial highlights

Valuation

  • Forward P/E -287.1
  • EV/Revenue 11.13

Profitability

  • Revenue Growth 37.9%
  • Gross Margin 81.7%
  • Operating Margin -14.8%
  • Net Margin -139.2%
  • ROE -703.0%

Financial strength

  • Cash $438.29M
  • Debt $762.95M
  • Net Cash $-324.66M
  • Free Cash Flow $54.87M
  • Current Ratio 2.86

Similar companies

Peers in Biotechnology, ranked by Financial Health.

Company Ticker
Price Current price

Latest quoted price for the name. Helps anchor the setup in today’s market level.

Health Entry

View all in Biotechnology →

FAQ

How Compound Radar scores and tracks Mirum Pharmaceuticals, Inc. (MIRM).

View Methodology & FAQ →